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EPIDERMAL ADENYLATE CYCLASE: STIMULATION OF THE HISTAMINE (H2) 
RECEPTOR BY TOLAZOLINE 
HAJIME hzuKA, M.D. , KENJJ ADACHI , M.D .. PH.D., KENNETH M. HALPRIN, M.D., 
AND VICTOR LEVINE, B.Sc. 
Veterans Administration Hospital and the Department of Dermatology. University of Miami School of Medicine, 
Miami. Florida, U.S. A . 
Tolazoline (2-benzyl-2-imidazolineJ activated adenylate cyclase in pig epidermal slices 
resulting in the accumulation of cyclic AMP. This effect was highly potentiated by thl:! 
addition of the cyclic AMP-phosphodiesterase inhibitor, theophylline. Specific histamine 
(H2) receptor inhibitors (metiamide and cimetidine) completely blocked the tolazoline 
activation of adenylate cyclase. At low concentrations (10-100 J..I.M). a histamine (H ,) 
receptor inhibitor (diphenhydramine) and a ,a-adrenergic blocker (propranolol) did not 
inhibit this effect. The stimulation of cyclic AMP formation by the combination of tolazoline 
and histamine was about the same as the stimulation by histamine alone (nonadditive), 
whereas the stimulatory effects by tolazoline and epinephrine were additive. These data 
suggest that tolazoline, an ex-adrenergic blocker, a lso activates adenylate cyclase at the 
histamine (H2) receptor site which is distinct from the ,8-adrenergic receptor site. Another 
ex-adrenergic blocker, phentolamine, did not have this effect. 
Tolazoline, a peripheral vasodilator and ex-adre-
nergic blocking agent has been used to treat 
peripheral vascular diseases. Recently Yellin, 
Sperow, and Buck fl ] reported that gastric acid 
secretion and atrial stimulation of sinus rate in-
duced by tolazoline were both antagonized by two 
specific histamine (H2) receptor antagonists, buri-
mamide and metiamide. Since histamine (H 2) 
responses have been linked to the generation of 
cyclic AMP in some tissues [2,3), including epider-
mis [4], the data by Yellin, Sperow, and Buck 
prompted us to investigate the effect of tolazoline 
on epidermal adenylate cyclase. Our results re-
ported in this communication suggest that tolazo-
line can activate pig epidermal adenylate cyclase 
at the histamine (H2) receptor site and thereby 
cause an accumulation of cyclic AMP. 
MATERIALS AND METHODS 
The ell.-perimental procedures were essentially the 
same as described previously [5). Skin slices were 
taken from th e backs of domestic pigs by a keratome 
(Storz Instruments, St. Louis. Mo.) adjusted to a 0.3-
rnm setting without anesthetics. The skin thus ob-
tained was predominantly epidermis (80-90'*>· The 
slices were cut into 5 x 5 mm squares and preincubated 
in Hank's medium for 15 min at 37"C to standardize 
the initial cyclic AMP level in the epidermal squares 
[5,6]. After the preincubation, the epidermal squares 
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were floa ted for 5 or 10 min at. 37"C in Hank's medium 
containing various compounds to be tested. At least 
two epidermal squares were used for each experiment. 
The cyclic AMP contents in t he epidermal squares 
were measured by Gilman's protein binding method 171 
with minor modifications [6). The binding assay was 
done in duplicate. Protein was measured by the method 
of Lowry et al 18). Chemicals and drugs were all 
prepared fresh before each experiment and the pH of 
the incubation media was adjusted to 7. Tolazoline 
hydrochloride, and phentolamine mesylate were ob-
tained from CIBA Pharmaceutical Co. (Summit, New 
J ersey), epinephrine was the product of Parke Davis 
(Detroit, Michigan). Metiamide, cimetidine, and 4-
methyl histamine were a kind gift from Dr. Brimble-
combe and Mr. Paul , Smith, Kline and French Lab. 
All other chemicals were purchased from Sigma Chem-
ical Co. (St. Louis, Missouri). 
RESULTS 
Effect o(Tolazoline 
Tolazoline caused an increase in the intracellu-
lar cyclic AMP level (Fig 1). The maximal increase 
was attained by 5 min and then gTaduaJJy de-
creased over 30 min. The addition of theophylline 
greatly potentiated the effect of tolazoline, and 
the cyclic AMP level reached its maximal level in 
a bout 10 min. Theophylline alone had little effect 
on the cyclic AMP content. The effect of different 
concentrations of tolazoline is shown in Fig 2. The 
incubation medium contained 5 mM theophylline 
and the incubation was carried out for 10 min. 
The increase in the intracellular cyclic AMP level 
was dose-dependent and the maximal effect was 
obtained at about 3 mM. Lineweaver-Burk plots 
(the insert of Fig 2) show the apparent Ka for 
tolazoline at about 1 mM (1.34 x lQ- 3 M) . This Ka 
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FIG 1. Time course of the effect of tolazoline on the 
intracellular cyclic AMP content. Details of the experi-
mental condition are given in the "Materials and Meth-
ods" section. The concentration of tolazoline added was 
2 mM and that of theophylline 5 mM (0 tolazoline only; 
!:::, tolazoline + theophylline; and X = control (no 
addition). 
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Frc 2. The effect of tolazoline concentration. Tissues 
were incubated with various concentrations of tolazo-
line for 10 min. Theophylline !5 mM) was added to all 
the incubation media. The insert shows Lineweaver-
Burk plots of the concentration curve. 
value is much higher than that of histamine 
where the apparent Ka was about 6 X w-'· M [4]. 
Phentolamine (mesylate), another a-adrenergic 
blocking agent, had no effect on cyclic AMP accu-
mulation up to a concentration of 4 mM (data not 
shown). 
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Effect of Histamine (H 1) and (H 2 ) Inhibitors 
To assess the characteristics of the receptor for 
tolazoline, two specific histamine antagonists 
were used: metiarnide and cimetidine (a nonthi-
ourea analogue ofmetiamide), both specific antag-
onists of the fH2J receptor [9,10,11] and diphenhy-
dramine, a classical antihistamine which antago-
nizes the activation of the (H ,) receptor. Figure 3 
shows the effect of increasing concentrations of 
metiarnide and cimetidine on the accumulation of 
cyclic AMP induced by 3 mM of tolazoline. Both 
metiamide and cimetidine clearly blocked the 
stimulatory effect of tolazoline in a dose-dependent 
manner. The 10 50 (concentration of the drug 
giving 50~ of its maximal inhibition) of metiamide 
and cimetidine were about 1 - 2 !J-M. Figure 4 
shows the effects ofmetiamide, diphenhydramine, 
and propranolol (a J3-adrenergic receptor blocker) 
on the stimulation of adenylate cyclase by tolazo-
line. At low inhibitor concentrations (below 100 
!J-M) only metiamide was able to block the effect 
of tolazoline. At high inhibitor concentrations 
(above 100 !J-M) diphenhydramine and propranolol 
also inhibited the effect. 
Interrelationship B etween the Effects of 
Tolazoline, H istamine and Epinephrine 
The effects of tolazoline, histamine, epineph-
rine, and their combinations on cyclic AMP levels 
are shown in the Table (A and Bl. In this experi-
ment, all drugs were used at their saturation 
concentrations (c.f. , Fig 2 and references 4 and 5). 
The cyclic AMP accumulation by the simultaneous 
addition of tolazoline and epinephrine was about 
equal to the sum of the increases due to each drug 
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Frc 3. The effects of metiamide and cimetidine at 
various concentrations. Cyclic AMP contents were 
measured after the incubation with 3 mM tolazoline 
and various concentration of (H2) antagonists. Incuba-
tion was done for 10 min with 5 mM theophylline. te , 
metiamide. 0, cimetidine). Abscissa indicates the con-
centrations of (H2l antagonists, metiamide, and cime-
tidine. 
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F1c 4 The effect of metiamide, d iphenhydramine. and 
propra nolol at various concentrations. The experimen-
tal condition was the same as in Fig 3 except that 
different kinds of inhibitors were used . D = met1amide, 
a n antihistamine (H2); 0 = diphenhydra mine, a n an-
tihistamine (H,); 6. = propra nolol , a {3-adrenergic 
blocker; X = control (no addition). 
added singly; i.e., the effects were additive. On 
the other hand, the cyclic AMP accumulation by 
any combination of tolazoline and <H2 ) agonists, 
histamine or 4-methyl-histamine, does not exceed 
the stimulation due to histamine alone, i.e., the 
effects were nonadditive. The significance of the 
additive or nonadditive effects of drugs is dis-
cussed below. 
DISCUSSION 
The present studies indicate that tolazoline can 
activate epidermal adenylate cyclase resulting in 
the a ccumulation of cyclic AMP. Since this effect 
was highly potent iated by the addition of theo-
phylline, the accumulation of cyclic AMP by tola-
zoline was not due to phosphodiesterase inhibition 
but to the stimulation of adenylate cyclase. We 
have previously shown [ 4] that the cyclic AMP 
increase in skin by the simultaneous addition of 
histamine and epinephrine was about equal to 
the sum of the increase due to each drug added 
singly, i.e. , histamine and epinephrine showed 
the "additive" effect. The data suggest the occur-
rence of separate receptor sites for each drug, i.e., 
this histamine and ,a-adrenergic receptors. Pres-
ent studies show that the stimulatory effects of 
tolazoline and epinephrine are "additive" but 
those of tolazoline and histamine (or 4-methyl-
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The effect of tolazoline, epinephrine, histamine and 4-
methy/-histamine on the cyclic AMP level in pig 
epidermis 
None 0 min 
5 min 
Additions 
A. Tolazoline 
Epinephrine 
Tolazoline & epinephrine 
B. Tolazoline 
4-Methyl-histamine 
Histamine 
Tolazoline & 4-methyl-histamine 
Tolazoline & histamine 
4-Methyl-histamine & histamine 
Tolazoline & 4-methyl-histamine 
& hista mine 
Cyclic AMP 
(pmoles/mg 
protein) 
1.1 
0.7 
25.1 
17.8 
48.2 
29.3 
38.8 
48.4 
49.3 
53.0 
45.4 
52.0 
Concentrations of drugs added were tolazoline = 5 
mM, epinephrine = 50 p.M. histamine = 2 mM, a nd 4-
methyl histamine = 1.6 mM. The incubation was car-
ried out for 5 min at 37•c. No phosphodiesterase inhib-
itors were added in this experiment. 
histamine) are not "additive". Furthermore, the 
stimulatory effect by tolazoline was not counter-
acted by propranolol, a ,a-adrenergic blocker. 
These results suggest that tolazoline acts on the 
histamine receptor site which is distinct from the 
,a-adrenergic receptor site. Recently two different 
histamine receptors, (H 1l and CH~). have been 
recognized. Since the histamine activation of skin 
adenylate cyclase is blocked by low concentration 
of metiamide but not by diphenhydramine [4], the 
histamine adenylate cyclase system in skin is 
defined as histamine CH 2 J receptor site. The pres-
ent studies also showed that the tolazoline activa-
tion was completely blocked by metiamide <and 
also by cimetidine), but not by diphenhydramine 
at the low concentration. The results are consist-
ent with a view that the tolazoline action on skin 
adenylate cyclase is mediated by the histamine 
CH2) receptor site. 
The effect of tolazoline on the histamine cH2) 
receptor appears to be not strong enough to cause 
full activation. The maximal activation by tolazo-
line was much less than that produced by hista-
mine. In our epidermal system the addition of 
histamine caused further accumulation of cyclic 
AMP even after the maximal stimulation by tola-
zoline. Also, the activation constant for histamine 
(60 MM) was much lower tha n that of tolazoline ( 1 
mM). These facts suggest that the "histamine-
like" action of tolazoline is a weak one and proba-
bly due to a weak affinity of tolazoline to the <H2) 
receptor site. The weak affinity of tolazoline may 
also explain the apparently nonspecific inhibition 
of tolazoline stimulation by diphenhydramine and 
propranolol at high concentrations (1 mM). 
Among the four receptor sites for activation of 
skin adenylate cyclase, ,a-adrenergic [5], prosta-
glandin E [12], h istamine (H2) 14], and adenosine 
Nou. 1977 
[13), tolazoline appears to act through the hista-
mine (H2 ) receptor. This study again stresses the 
multiple sites of action of drugs affecting the 
epidermal cyclic AMP system. 
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